Return to ovulation following the use of long-acting injectable contraceptives: a comparative study - PubMed (original) (raw)
Comparative Study
Return to ovulation following the use of long-acting injectable contraceptives: a comparative study
J Garza-Flores et al. Contraception. 1985 Apr.
Abstract
A comparative study was undertaken in twenty-four Mexican women who discontinued the use of depo-medroxyprogesterone acetate (DMPA) or norethisterone enanthate (NET-EN) to assess the time required for the return to menses and ovulation. All subjects were exposed to long-acting injectable contraceptives for at least one year, and were followed prospectively. Serum progesterone levels were determined weekly in all subjects beginning 3 months after the last progestogen injection. Mean time to return to ovulation occurred significantly earlier (p less than 0.001) after NET-EN (2.6 months) as compared with DMPA (5.5 months). No correlation between the return to ovarian function and the duration of steroid exposure was found. The overall data was interpreted as demonstrating a clear-cut difference between the two long-acting progestogens in terms of ovulation suppression.
Similar articles
- Long-acting hormonal contraceptives for women.
Garza-Flores J, Hall PE, Perez-Palacios G. Garza-Flores J, et al. J Steroid Biochem Mol Biol. 1991;40(4-6):697-704. doi: 10.1016/0960-0760(91)90293-e. J Steroid Biochem Mol Biol. 1991. PMID: 1958567 Review. - Acceptability of injectable contraceptives in Assiut, Egypt.
Salem HT, Salah M, Aly MY, Thabet AI, Shaaban MM, Fathalla MF. Salem HT, et al. Contraception. 1988 Dec;38(6):697-710. doi: 10.1016/0010-7824(88)90051-0. Contraception. 1988. PMID: 2975583 Clinical Trial. - A randomized, single blind comparative trial of norethindrone enanthate and depo-medroxyprogesterone acetate in Bangladesh.
Swenson I, Khan AR, Jahan FA. Swenson I, et al. Contraception. 1980 Mar;21(3):207-15. doi: 10.1016/0010-7824(80)90001-3. Contraception. 1980. PMID: 6446442 Clinical Trial. - A comparative study on the return to ovulation following chronic use of once-a-month injectable contraceptives.
Bassol S, Hernandez C, Nava MP, Trujillo AM, Luz de la Cruz D. Bassol S, et al. Contraception. 1995 May;51(5):307-11. doi: 10.1016/0010-7824(95)00080-t. Contraception. 1995. PMID: 7628206 Clinical Trial. - Pharmacodynamic effects of once-a-month combined injectable contraceptives.
Sang GW. Sang GW. Contraception. 1994 Apr;49(4):361-85. doi: 10.1016/0010-7824(94)90033-7. Contraception. 1994. PMID: 8013220 Review.
Cited by
- Risk of HIV-1 acquisition among women who use diff erent types of injectable progestin contraception in South Africa: a prospective cohort study.
Noguchi LM, Richardson BA, Baeten JM, Hillier SL, Balkus JE, Chirenje ZM, Bunge K, Ramjee G, Nair G, Palanee-Phillips T, Selepe P, van der Straten A, Parikh UM, Gomez K, Piper JM, Watts DH, Marrazzo JM; VOICE Study Team. Noguchi LM, et al. Lancet HIV. 2015 Jul;2(7):e279-87. doi: 10.1016/S2352-3018(15)00058-2. Lancet HIV. 2015. PMID: 26155597 Free PMC article. Clinical Trial. - Pharmacokinetic, biologic and epidemiologic differences in MPA- and NET-based progestin-only injectable contraceptives relative to the potential impact on HIV acquisition in women.
Heffron R, Achilles SL, Dorflinger LJ, Hapgood JP, Kiarie J, Polis CB, Steyn PS. Heffron R, et al. Contraception. 2019 Apr;99(4):199-204. doi: 10.1016/j.contraception.2018.12.001. Epub 2018 Dec 18. Contraception. 2019. PMID: 30576636 Free PMC article. - U.S. Selected Practice Recommendations for Contraceptive Use, 2024.
Curtis KM, Nguyen AT, Tepper NK, Zapata LB, Snyder EM, Hatfield-Timajchy K, Kortsmit K, Cohen MA, Whiteman MK; Contributors. Curtis KM, et al. MMWR Recomm Rep. 2024 Aug 8;73(3):1-77. doi: 10.15585/mmwr.rr7303a1. MMWR Recomm Rep. 2024. PMID: 39106301 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials